You are on page 1of 9

RESULT

A total of 137 patients who suffered from inoperable lung cancer were screened and 9 patients is
lost to follow up. Among the rest, patients was divided into two group of treatment ; standard
teratment and test treatment and were follow up for a period of 3 years or until death. Out of
these, for each treatment, 64 patiens received a standard treatment and test treatment. Baseline
characteristics of the two groups are shown in Table 1.
Treatment

Celltype
1- Squamous
2- Smallcell
3- Adeno
4- Large
Age in Years
Month from Diagnosis
Prior Therapy
Yes = 10
No = 0
Karnofsky Score

Standard
Treatment 1 (n=64)

Test
Treatment 2 (n=64)

13 (41.9%)
28 (62.1%)
9 (34.6%)
14 (53.9%)
57 ± 11 (54-60)
8.9 ± 9.0 (6.9-11.1)

18 (58.1%)
17 (37.9%)
17 (65.4%)
12 (46.3%)
60 ± 10 (57-62)
8.9 ± 12.5 (5.7-12.0)

20 (54.1%)
17 (45.9%)
44 (48.4%)
47 (51.6%)
58.20 ± 18.68
56.88 ± 21.17
Table 1 : Characteristic of Patients

From Table 1, the patients with Squamous celltype was 13 patients (41.9%) and 18 patients
(58.1%) for standard and test treatment respectively. For the Smallcell celltype, there was about
28 patients (62.1%) for standard treatment and 17 patients (37.9%) for test treatment.
Meanwhile, for patients with Adeno celltype, there was 9 and 17 patients for standard and test
treatment respectively. From the Large celltype, there was 14 patients and 12 patients for
standard and test treatment respectively.
The mean (±SD) age for standard treatment is 57 years (range, 55-60), whereas for test treatment
is 60 years (range, 57-62). The standard and test treatment was conducted from an average 8.9
months from the diagnosis with (range, 6.9-11.1). and (range, 5.7-12.0), respectively. Among the
patients, 20 patients for standard treatment and 17 patients for test treatment has a prior therapy
history.

05. it was 52 days. .777 Median 80 I QR 137 80 Percent 60 40 20 0 0 200 400 600 Survival in Days 800 1000 Figure 1 : Kaplan-Meier for both treatments Survival Plot for Survival in Days Kaplan-Meier Method Censoring Column in Status 100 Treatment 1 2 Percent 80 Table of Statistics Mean Median I QR 123.928>0. The difference was not statistically significant (p=0. Figure 2 shows the Kaplan-Meier survival curve of all patients. overall median survival when both groups were taken together was 80 days.Survival Plot for Survival in Days Kaplan-Meier Method Censoring Column in Status 100 Table of Statistics Mean 132.928 103 135 142. log rank test).061 52 116 60 40 20 0 0 200 400 600 Survival in Days 800 1000 Figure 2 : Kaplan Meier survival analysis by treatment groups From Figure 1. Median survival in the standard treatment group was 103 days and in test treatment group.

Survival difference between the the celltypes was statistically significant (p=0.333 53 121 60 40 20 0 0 200 400 600 Survival in Days 800 1000 Figure 4 : Kaplan Meier survival analysis with different celltype according to test treatment (T2) For the test treatment group.05. the median survival for patients with Squamous celltype (C1).0% patients with Smallcell survived more than 150 days.8% patients for Large celltype survived more than 278 days.790 110 102 94.000<0. 25 days. the median survival for patients with Squamous celltype (C1).889 92 105 200. From the Figure 4 above. log rank test).056 48 60 132. 8. 12.522 177 145 60 40 20 0 0 100 200 300 400 Survival in Days 500 600 Figure 3 : Kaplan Meier survival analysis with different celltype according to standard treatment (T1) For the standard treatment group.167 25 67 62.022<0.6% of patients with Adeno celltype survived more than 35 days and 7.05. 48 days and 53 days respectively (Figure 4). Smallcell (C2).362 201 359 47.Survival Plot for Survival in Days (T1) Kaplan-Meier Method Censoring Column in Status 100 Celltype 1 2 3 4 Percent 80 Table of Statistics Mean Median I QR 136.793 52 119 72.3% patients with Squamous celltype survived more than 300 days. 13. log rank test). From the figure 3 above. 92 days and 177 days respectively (Figure 3). Adeno (C3) and Large (C4) was 201 days. 52 days. Survival difference between the the celltypes was statistically significant (p=0. Smallcell (C2). Survival Plot for Survival in Days (T2) Kaplan-Meier Method Censoring Column in Status 100 Celltype 1 2 3 4 Percent 80 Table of Statistics Mean Median I QR 293.2% patients with Squamous celltype . Adeno (C3) and Large (C4) was 110 days. 55.

435) . Survival Plot for Survival in Days T1 Kaplan-Meier Method Censoring Column in Status 1 100 Age in Years <60 ≥60 Percent 80 Table of Statistics Mean Median I QR 133.381 49 182 100.488 61 87 60 40 20 0 0 200 400 600 Survival in Days 2 800 1000 Figure 6 : Kaplan Meier survival analysis for Age according to test treatment (T2) (p=0.05. Meanwhile the median survival time for patients with age more than or equal to 60 years is 72 days.9% of patients with Adeno celltype survived more than 90 days and 16. the median survival time for standard treatment (T1) patients with age less than 60 years is 100 days. log rank test).6% patients with Smallcell survived more than 99 days.000 100 198 104.7% patients for Large celltype survived more than 200 days.459>0. 13. 5. Survival Plot for Survival in Days T2 Kaplan-Meier Method Censoring Column in Status 2 100 Age in Years <60 ≥60 Percent 80 Table of Statistics Mean Median I QR 185. Survival difference between the age was statistically not significant (p=0.211 72 124 60 40 20 0 0 100 200 300 400 Survival in Days 1 500 600 Figure 5 : Kaplan Meier survival analysis for Age according to standard treatment (T1) (p=0.459) Figure 5 shows that.survived more than 500 days.

log rank test).435>0.241 52 109 63.627 92 134 132.000 51 0 60 40 20 0 0 200 400 600 Survival in Days 2 800 1000 Figure 8 : Kaplan Meier survival analysis for Month from Diagnosis according to test treatment (T2) (p=0. Survival difference between the two groups was statistically not significant (p=0.Meawhile for test treatment.250 110 112 8. Survival Plot for Survival in Days T1 Kaplan-Meier Method Censoring Column in Status 100 Month from Diagnosis 1-20 20-40 40-60 Percent 80 Table of Statistics Mean Median I Q R 116. the median survival time for patients with age less than 60 years is 49 days.005) Survival Plot for Survival in Days T2 Kaplan-Meier Method Censoring Column in Status 100 Month from Diagnosis 1-20 20-40 80-100 Percent 80 Table of Statistics Mean Median I QR 135. Figure 6 shows that. Meanwhile the median survival time for patients with age more than or equal to 60 years is 61 days.000 8 0 60 40 20 0 0 100 200 300 400 Survival in Days 1 500 600 Figure 7 : Kaplan Meier survival analysis for Month from Diagnosis according to standard treatment (T1) (p=0.800 25 88 51.05.531) .

.001<0.480 45 61 232. the median survival time for KPS (10-30) was 18 days. log rank test). 13 patients belong to Group 1. according to standard treatment (T1).Survival Plot for Survival in Days T1 Kaplan-Meier Method Censoring Column in Status 1 100 Karnofsky Score 10-30 40-60 70-90 Percent 80 Table of Statistics Mean Median I QR 32. Group 3 (70-90). 29 patients and 26 patients belong to Group 2 and 3 respectively. Survival Plot for Survival in days T2 Kaplan-Meier Method Censoring Column in Status 2 100 Karnofsky Score 10-30 40-60 70-90 Percent 80 Table of Statistics Mean Median I QR 25.379 63 156 146. Group 1 (10-30). 25 patiens and 26 patients belong to Group 2 and 3. for test treatment.692 133 256 60 40 20 0 0 200 400 600 Survival in days 2 800 1000 Figure 10 : Kaplan Meier survival analysis for KPS according to test treatment (T2) (p=0.346 117 70 60 40 20 0 0 100 200 300 400 Survival in Days 1 500 600 Figure 9 : Kaplan Meier survival analysis for KPS according to standard treatment (T1) (p=0. 45 days for KPS (4060) and 133 days for KPS (70-90).000<0. log rank test). Survival difference between the KPS scores was statistically significant (p=0. Figure 9 shows that.000) Meanwhile. The Figure 10 also shows that the survival difference between the KPS scores was statistically significant (p=0. Group 2 (40-60).05.889 18 10 114. The median survival time for KPS (10-30) was 21 days.001) Patients were divided into 3 groups based on their Karnofsky performance score (KPS) . 63 days for KPS (40-60) and 117 days for KPS (70-90).05.154 21 18 73. 9 patients belong to Group 1.

348) Figure 12 shows that for test treatment. Meanwhile the median survival time for patients with no prior thearpy is 52 days. Survival difference between the two groups was statistically not significant (p=0.882 51 182 60 40 20 0 0 200 400 600 Survival in Days 2 800 1000 Figure 12 : Kaplan Meier survival analysis for Prior Therapy according to test treatment (p=0.277 52 86 194.591 95 121 105.600 56 141 60 40 20 0 0 100 200 300 400 Survival in Days 500 600 Figure 11 : Kaplan Meier survival analysis for Prior Therapy according to standard treatment (p=0.700>0.Survival Plot for Survival in Days T1 Kaplan-Meier Method Censoring Column in Status 100 Prior Therapy No Yes Percent 80 Table of Statistics Mean Median I Q R 120.700) For standard treatment. the median survival time for patients with prior therapy is 56 days (Figure 10). Meanwhile the median survival time for patients with no prior thearpy is 95 days. Survival Plot for Survival in Days T2 Kaplan-Meier Method Censoring Column in Status 2 100 Prior Therapy No Yes Percent 80 Table of Statistics Mean Median I QR 104. . log rank test). the median survival time for patients with prior therapy is 51 days.05.

0049785 7. prior rank test).068 -0.0450792 M. is the result of testing the prognostic factor that influence the risk of death in the VA lung cancer using Cox Proportional Hazard Model. Based on this output also.0100087 K.D -0.0316551 0.D versus treat. it can be concluded that K. log Regression with Life Data: S.312 -0. Response Variable: S.54119 treat -0.0167327 0.T. Figure 10 : Cox Proportional Hazard .12 0. C.S.0089507 -0. we can performed our new model with the known parameters obtained from the result.182451 -1.0090893 0.0218412 0.33 0.01 0.0029654 0.173257 C.0145776 Age 0.D.0539610 Shape 1 Log-Likelihood = -724.000 1.14891 0.282936 0.T -0.75664 4.000) that have big influence on the hazard of death or survival times of a patients.S 0. From the result that obtained in MINITAB.014 Figure 13 : Cos Proportional Hazard Figure 13 aboves.740 -0.710360 4.610 -0.0% Normal CI Predictor Coef Error Z P Lower Upper Intercept 3.0188968 prior 0. M.0010820 0.Survival difference between the two groups was statistically not significant (p=0.05.0353214 0.51 0.348>0.43 0.0111529 0. The proportional hazards regression model for the ith individual of male patients are then  1Treatmenti   2Celltype2i   3 Karnofsky Score3i   hi  t   exp    4 Months from Diagnosis4i   5 Age in Years5i     Prior Therapy  6 6i   Where the subscript i on an explanatory variables represents the value of that variable for ith individual.000 0.541940 0.0747321 -1.S referred to Karnofsky Score has p-value (p=0.0255636 0.09 0.0205085 0.136463 0.D Censoring Information Count Uncensored value 128 Right censored value 9 Censoring value: Status = 0 Estimation Method: Maximum Likelihood Distribution: Exponential Regression Table Standard 95. K.184342 0. Age.905 -0.83 0.

0029654 Months from Diagnosisi  0. 0.184342 Treatmenti  0.0111529 Prior Therapy  i   .136463 Celltypei  0.0010820 Age in Yearsi   0.0353214 Karnofsky Scorei   hi  t   exp  0.